Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Size By Infection Type (Hospital-acquired, Community-acquired), By Drug Type (Oral & Parental Antibiotics, Topical Antibiotics), By Route of Administration (Oral, Parental, Topical), By Distribution Channel (Hospital, Retail, Online),

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Size and Forecast

Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market size was valued at USD 11.49 Billion in 2024 and is projected to reach USD 23.94 Billion by 2031, growing at a CAGR of 9.6% from 2024 to 2031.

• Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are severe bacterial infections of the skin and underlying soft tissues that must be treated immediately with antibiotics. They include cellulitis, erysipelas, severe cutaneous abscesses, and wound infections.
• ABSSSIs are typically caused by Gram-positive bacteria, particularly Staphylococcus and Streptococcus species, such as methicillin-resistant Staphylococcus aureus (MRSA). If not treated effectively, these infections can cause severe morbidity, with symptoms including redness, swelling, discomfort, and warmth at the affected site.

Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Dynamics

The key market dynamics that are shaping the acute bacterial skin and skin structure infection market include

Key Market Drivers

• Increasing Prevalence of Skin and Soft Tissue Infections The increased frequency of skin and soft tissue infections, especially ABSSSIs, is a major driver of this market. According to the US Centers for Disease Control and Prevention (CDC), there were approximately 14.2 million outpatient consultations for skin and soft tissue infections in the United States in 2015. This high prevalence highlights the urgent need for improved therapies for ABSSSI.
• Rising Antibiotic Resistance The growing concern about antibiotic-resistant bacteria is pushing the development of new treatments for ABSSSI. According to the World Health Organization (WHO), antibiotic-resistant bacterial infections killed more than 1.2 million people in 2019. This concerning development is driving the need for new medicines and treatment options for ABSSSIs.
• Increasing Healthcare ExpenditureThe global increase in healthcare spending is boosting the ABSSSI market. According to the World Bank, worldwide health expenditure as a proportion of GDP increased from 8.5% in 2000 to 9.8% in 2019. This increased healthcare investment is improving access to therapies for illnesses such as ABSSSIs, especially in wealthy countries.

Key Challenges

• High Development Costs Significant research and development investments are required to create novel ABSSSI medicines and therapies. The high costs of this technique deter pharmaceutical companies from investing in this field, restricting product availability and innovation.
• Limited Treatment Options Despite the increasing demand for effective ABSSSI treatments, there are just a few authorized medications available. The scarcity of accessible treatment choices limits patient options and inhibits the market from growing as quickly as it can.
• Antibiotic Resistance Antibiotic-resistant bacterial strains are becoming increasingly common, making it difficult to treat ABSSSIs effectively. This diminishes the efficacy of current antibiotics while increasing the demand for innovative therapeutic options, which are difficult and time-consuming to develop.

Key Trends

• Growing Awareness and Prevalence The market is being driven by increased awareness of the prevalence of ABSSSI, as well as rising incidence rates. This trend is caused by an increase in skin and soft tissue infections, particularly among immunocompromised people and those suffering from chronic conditions.
• Advancements in Treatment Options Technological advances in diagnoses and treatment techniques are transforming the ABSSSIs market. Advanced imaging techniques and speedy diagnostic tests promote early detection, resulting in timely interventions and better patient outcomes.
• R&D Initiatives by Pharmaceutical Companies Pharmaceutical companies are increasingly focusing on R&D. This includes the creation of novel medications and therapy targeted to antibiotic-resistant strains, thereby meeting previously unmet medical requirements.

Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Regional Analysis

Here is a more detailed regional analysis of the acute bacterial skin and skin structure infection market

North America

• According to Market Research, North America is estimated to dominate the acute bacterial skin and skin structure infection market over the forecast period. Skin and soft tissue infections, including ABSSSIs, are common in North America, especially in the United States. In 2014, the United States Centers for Disease Control and Prevention (CDC) reported roughly 3.4 million emergency department visits for skin and soft tissue infections. This high prevalence increases the demand for ABSSSI therapies in the region.
• North America has a well-developed healthcare system and high healthcare spending, which allows for improved detection and treatment of ABSSSIs. According to the Centers for Medicare and Medicaid Services, healthcare spending in the United States increased by 4.6% in 2019, to USD 3.8 Trillion, or $11,582 per person. This level of spending encourages the use of newer, more effective therapies for ABSSSI.
• Furthermore, MRSA is a common cause of ABSSSIs, and its presence in North America serves as a substantial market driver. The CDC estimates that approximately 2% of the population has MRSA. In 2017, there were around 323,700 cases of MRSA in hospitalized patients in the United States. This high occurrence of antibiotic-resistant illnesses necessitates the development of sophisticated ABSSSI treatments in the region.

Europe

• Europe region is estimated to exhibit substantial growth during the forecast period. Europe has a high incidence of skin and soft tissue infections, particularly ABSSSIs. According to the European Centre for Disease Prevention and Control (ECDC), surgical site infections, a kind of ABSSSI, were reported in 3.2% of surgical procedures in Europe in 2019. This high prevalence increases the demand for effective therapies in the region.
• The increasing prevalence of antibiotic-resistant bacteria in Europe is driving the discovery and implementation of innovative treatments for ABSSSIs. According to the ECDC, over 33,000 persons in the EU/EEA died as a result of antibiotic-resistant bacterial illnesses in 2019. Methicillin-resistant Staphylococcus aureus (MRSA), a prevalent cause of ABSSSIs, is still a major public health concern, with MRSA accounting for more than 25% of Staphylococcus aureus isolates in seven of the 29 countries studied.
• Furthermore, the aging of Europe’s population, as well as the rise of chronic diseases, help to drive the ABSSSI market forward. According to Eurostat, the proportion of people aged 65 and up in the EU is expected to rise from 20.3% in 2019 to 29.4% in 2050. ABSSSIs are more likely to affect older persons and those with chronic diseases such as diabetes. According to the International Diabetes Federation, 59 million adults in Europe had diabetes in 2019, and this figure is anticipated to climb to 68 million by 2045, thereby increasing the incidence of ABSSSIs.

Asia Pacific

• The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia Pacific region has a large population, which naturally results in a higher incidence of ABSSSI cases. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region’s population is predicted to increase from 4.3 billion in 2020 to 4.7 billion in 2050. This population increase translates to a larger patient pool for ABSSSIs, which drives market growth.
• Diabetes poses a considerable risk for skin infections, especially ABSSSIs. According to the International Diabetes Federation (IDF), the number of adults living with diabetes in the Western Pacific region (which includes much of Asia) is anticipated to rise from 163 million in 2019 to 212 million by 2045. The rising prevalence of diabetes is anticipated to contribute to an increased incidence of ABSSSIs in the region.
• Furthermore, the Asia Pacific region is rapidly improving its healthcare infrastructure and access. According to the World Health Organization (WHO), health expenditure as a proportion of GDP in Southeast Asia rose from 3.5% in 2000 to 4.4% in 2017. Improved healthcare spending and infrastructure development are improving diagnostic and treatment capabilities for illnesses such as ABSSSIs, resulting in market growth.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) MarketSegmentation Analysis

The Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market is segmented based on Infection Type, Drug Type, Route of Administration, Distribution Channel, and Geography.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Infection Type

• Hospital-acquired ABSSSI
• Community-acquired ABSSSI

Based on Infection Type, the market is segmented into Hospital-acquired ABSSSI and Community-acquired ABSSSI. The hospital-acquired ABSSSI segment is estimated to dominate the acute bacterial skin and skin structure infection market due to the high incidence of hospital-acquired ABSSSI cases caused by variables such as impaired skin integrity, the presence of multi-drug resistance organisms in healthcare settings, and immunosuppressed patients’ susceptibility to severe infections.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Drug Type

• Oral & Parental Antibiotics
• Topical Antibiotics

Based on Drug Type, the market is segmented into Oral & Parental Antibiotics and Parental Antibiotics. The oral & parental antibiotics segment is estimated to dominate the acute bacterial skin and skin structure infection market during the forecast period owing to their great efficiency against a wide spectrum of bacterial illnesses and convenience of administration via the oral route. Parenteral antibiotics are especially important in severe cases because they provide increased bioavailability and tissue penetration, which is critical for treating illnesses such as bacteremia and sepsis.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Route of Administration

• Oral
• Parental
• Topical

Based on the Route of Administration, the market is segmented into Oral, Parental, and Topical. The parental segment is estimated to dominate the acute bacterial skin and skin structure infection market because parenteral antibiotics can quickly enter the bloodstream and successfully battle severe ABSSSI cases. The parenteral method is preferable for its quick drug administration and tailored treatment approach, particularly in urgent ABSSSI cases requiring prompt action.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Based on the Distribution Channel, the market is segmented into Hospital, Retail, Online, and Others. The hospital pharmacies segment is estimated to dominate the acute bacterial skin and skin structure infection market. Hospital pharmacies play an important role in ABSSSI therapy because they provide prompt access to essential medicines and work closely with healthcare teams to develop antibiotic regimens. Furthermore, hospital pharmacies help patients make a smooth transition to outpatient care by giving drugs upon release, assuring thorough and efficient ABSSSI therapy.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the acute bacterial skin and skin structure infection market is classified into North America, Europe, Asia Pacific, and the Rest of the World. According to the analyst, North America is estimated to dominate during the forecasted period due to leading pharmaceutical companies’ substantial research operations, a focus on creating anti-MRSA medications, and the introduction of new products. North America’s market revenue is predicted to remain dominant due to the region’s robust healthcare infrastructure and widespread awareness of ABSSSIs.

Key Players

The “Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Inc., Merck & Co., Inc., AstraZeneca plc, Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Sanofi S.A., Paratek Pharmaceuticals, Inc., and Melinta Therapeutics, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Acute Bacterial Skin and Skin Structure Infection Market Recent Developments

• In July 2021, Melinta Therapeutics, a pharmaceutical firm, released KIMYRSA, as a lipoglycopeptide antibiotic efficacious for treating acute bacterial skin and skin structure infections (ABSSSI) in a single 1200mg injectable dose.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any